| 臺大學術典藏 |
2022-08-19T00:20:57Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.; Chang D.-Y.; Hu F.-C.; Shao Y.-Y.; CHIUN HSU; Lin Z.-Z. |
| 臺大學術典藏 |
2022-08-19T00:20:57Z |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
Cheng A.-L.; Meng R.; Chao Y.; Hsieh T.-Y.; Huang W.-T.; Hwang W.-S.; Yu C.-W.; Hsieh R.-K.; Huo T.-I.; Yang T.-S.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:57Z |
A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: A novel approach by using meta-regression
|
Shen Y.-C.; CHIUN HSU; Cheng C.-C.; Hu F.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:56Z |
Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression
|
Yeh K.-H.; Cheng C.-C.; Cheng A.-L.; Hu F.-C.; Shen Y.-C.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:55Z |
Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy
|
Shau W.-Y.; Chen T.-J.; Yang S.-H.; Huang S.-M.; CHIUN HSU; Lu Y.-S.; Cheng A.-L.; Lin C.-H.; Kuo Y.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:55Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shen Y.-C.; Hsu C.-H.; Cheng A.-L.; CHIUN HSU; Lin Z.-Z.; Lu L.-C.; Shao Y.-Y. |
| 臺大學術典藏 |
2022-08-19T00:20:55Z |
Comparative microRNA detection from precursor-microRNA-transfected hepatocellular carcinoma cells by capillary electrophoresis with dual-color laser-induced fluorescence
|
Yang T.-H.; Ou D.-L.; CHIUN HSU; Huang S.-H.; Chang P.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:55Z |
erratum: Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression (Gastric Cancer (2012) 15(265-280) DOI 10.1007/s10120-011- 0106-5)
|
CHIUN HSU; Shen Y.-C.; Cheng C.-C.; Cheng A.-L.; Hu F.-C.; Yeh K.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:54Z |
The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines
|
Cheng A.-L.; Lu Y.-S.; Chen W.-W.; Chang D.-Y.; Huang S.-M.; Lin C.-H.; CHIUN HSU; Lin M.-H.; Huang C.-S. |
| 臺大學術典藏 |
2022-08-19T00:20:54Z |
Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients
|
Yeh K.H.; Hu F.C.; Chang S.Y.; Kao H.F.; Chen Y.C.; Chien S.F.; Chen I.C.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:53Z |
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
|
Liu S.-H.; Cheng A.-L.; Lin C.-Y.; Chang C.-Y.; Lin K.-L.; CHIUN HSU; Ou D.-L.; Shen Y.-C. |
| 臺大學術典藏 |
2022-08-19T00:20:53Z |
Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway
|
Liou J.-Y.; CHIUN HSU; Cheng A.-L.; Lin L.-I.; Lee B.-S.; Chang Y.-C.; Ou D.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:53Z |
14-3-3�` Overexpression Contributes to Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma
|
Wu Y.-M.; Liou J.-Y.; Wang J.; CHIUN HSU; Chen S.-C.; Liang S.-M.; Ko B.-S.; Jan Y.-J.; Liu T.-A. |
| 臺大學術典藏 |
2022-08-19T00:20:52Z |
Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group
|
Kim W.S.; Kwong Y.-L.; Suh C.; Lim S.T.; Cheng A.-L.; Chng W.-J.; Lee J.; Intragumtornchai T.; Kim S.J.; CHIUN HSU; Song Y.-Q.; Tay K.; Hong X.-N.; Cao J.; Kim J.S.; Eom H.S.; Lee J.H.; Zhu J.; Chang K.-M.; Reksodiputro A.H.; Tan D.; Goh Y.T. |
| 臺大學術典藏 |
2022-08-19T00:20:51Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Liu K.-L.; Liang P.-C.; Shih T.T.-F.; Chen C.-H.; CHIUN HSU; Wu C.-H.; Shih I.-L.; Chen B.-B. |
| 臺大學術典藏 |
2022-08-19T00:20:51Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lai M.-S.; Yang J.C.-H.; Cheng A.-L.; Hsu C.-H.; Kuo R.N.-C.; Yeh Y.-C.; Shao Y.-Y.; CHIUN HSU; Shau W.-Y.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-08-19T00:20:50Z |
Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan
|
Chang Y.-T.; Chang M.-C.; Huang K.-W.; Tung C.-C.; CHIUN HSU; Wong J.-M. |
| 臺大學術典藏 |
2022-08-19T00:20:50Z |
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
|
Cheng A.-L.; Chen P.-J.; Liu T.-W.; Chang C.-S.; Tien H.-F.; CHIUN HSU; Tsou H.-H.; Lin S.-J.; Wang M.-C.; Yao M.; Hwang W.-L.; Kao W.-Y.; Chiu C.-F.; Lin S.-F.; Lin J. |
| 臺大學術典藏 |
2022-08-19T00:20:49Z |
Reply
|
CHIUN HSU; Chen P.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:48Z |
Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivity
|
Cheng A.-L.; Wang H.-P.; Tsai H.-J.; Wu M.-S.; Tzeng Y.-S.; Kuo S.-H.; Yeh K.-H.; Chen L.-T.; Lin C.-W.; Hsu P.-N.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:48Z |
Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma
|
Chang M.-C.; Chen C.-H.; Liang J.-D.; Tien Y.-W.; CHIUN HSU; Wong J.-M.; Chang Y.-T. |
| 臺大學術典藏 |
2022-08-19T00:20:47Z |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
|
Tak W.Y.; Yen C.-J.; Jeffers M.; Krissel H.; Kappeler C.; Rajagopalan P.; Hsieh W.-S.; Tay M.H.; Yeo W.; Park J.-W.; Poon R.T.P.; Rau K.-M.; CHIUN HSU; Yoon J.-H.; Lin C.-Y.; Choi H.J.; Heo J.; Lim H.Y. |
| 臺大學術典藏 |
2022-08-19T00:20:46Z |
H3K9 histone methyltransferase, KMT1E/SETDB1, Cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis
|
Wu P.-C.; Lu J.-W.; Yang J.-Y.; Lin I.-H.; Ou D.-L.; Lin Y.-H.; Chou K.-H.; Huang W.-F.; Wang W.-P.; Huang Y.-L.; CHIUN HSU; Lin L.-I.; Lin Y.-M.; James Shen C.-K.; Tzeng T.-Y. |
| 臺大學術典藏 |
2022-08-19T00:20:46Z |
Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review
|
Lim H.Y.; Kim J.S.; Orlando M.; Chen L.-T.; Chen J.-S.; CHIUN HSU; Oh D.-Y.; Park J.O. |
| 臺大學術典藏 |
2022-08-19T00:20:45Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Yang J.C.H.; Lai M.-S.; Cheng A.-L.; Cheng W.-F.; CHIUN HSU; Shao Y.-Y.; Yang Y.-Y.; Lai C.-L.; Shau W.-Y.; Kuo R.; Lin Z.-Z.; Kuo H.-Y. |
| 臺大學術典藏 |
2022-08-19T00:20:45Z |
A decade of changes in preferences for life-sustaining treatments among terminally ill patients with cancer
|
Chiang M.-C.; Liu L.N.; Sung Y.-C.; Hsieh C.-I.; Chang S.-Y.; Chang Y.-H.; Chang C.-S.; CHIUN HSU; Wen F.-H.; Liu T.-W.; Tang S.T. |
| 臺大學術典藏 |
2022-08-19T00:20:45Z |
Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014)
|
Cheng A.-L.; Han K.-H.; Jia J.-D.; Seong J.; CHIUN HSU; Chen B.-B.; Chen C.-H.; Ho M.-C.; Cheng J.C.-H.; Kokudo N.; Murakami T.; Yeo W. |
| 臺大學術典藏 |
2022-08-19T00:20:44Z |
Cough with bile
|
Liu K.-L.; CHIUN HSU; Chang C.-C. |
| 臺大學術典藏 |
2022-08-19T00:20:44Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; CHIUN HSU; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-08-19T00:20:43Z |
Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression
|
Ou D.-L.; Cheng A.-L.; Shao Y.-Y.; Feng Z.-R.; Lin L.-I.; Cheng Y.-C.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:43Z |
Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer
|
Chiang N.-J.; CHIUN HSU; Chen J.-S.; Tsou H.-H.; Shen Y.-Y.; Chao Y.; Chen M.-H.; Yeh T.-S.; Shan Y.-S.; Huang S.-F.; Chen L.-T. |
| 臺大學術典藏 |
2022-08-19T00:20:42Z |
Epithelioid Trophoblastic Tumor Around an Abdominal Cesarean Scar: A Pathologic and Molecular Genetic Analysis
|
Hsiue E.H.-C.; CHIUN HSU; Tseng L.-H.; Lu T.-P.; Kuo K.-T. |
| 臺大學術典藏 |
2022-08-19T00:20:42Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
CHIUN HSU; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H.; Guo J.-C.; Kuo T.-C.; Wu H.; Yang S.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:41Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; CHIUN HSU; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-08-19T00:20:40Z |
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
|
CHIUN HSU; Ou D.-L.; Cheng A.-L.; Chen C.-W.; Tan C.-T.; Lin Y.-Y. |
| 臺大學術典藏 |
2022-08-19T00:20:40Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
CHIUN HSU; Wang M.-J.; Cheng A.-L.; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:40Z |
Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYnote-028 study
|
Hansen A.R.; Cheng J.D.; Thanigaimani P.; Saraf S.; CHIUN HSU; Lee S.-H.; Ejadi S.; Even C.; Cohen R.B.; Le Tourneau C.; Mehnert J.M.; Algazi A.; Van Brummelen E.M.J. |
| 臺大學術典藏 |
2022-08-19T00:20:39Z |
Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection
|
CHIUN HSU; Taiwan Cooperative Oncology Group; Liu T.-W.; Chen P.-J.; Cheng A.-L.; Lin J.; Yuan Q.; Xia N.; Yao M.; Lin S.-J.; Chen J.-H.; Chang C.-S.; Pei S.-N.; Tsou H.-H.; Yang H.-C. |
| 臺大學術典藏 |
2022-08-19T00:20:39Z |
Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis
|
Liu Q.; Lin A.-H.; Tang L.-L.; Sun Y.; Ma J.; CHIUN HSU; Mao Y.-P.; Li W.-F.; Zhou G.-Q.; Chen L.; Huang C.-L.; Liu J.-Q.; Du X.-J.; Chen Y.-P.; Xu C. |
| 臺大學術典藏 |
2022-08-19T00:20:39Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group; Ni Y.-H.; Lin C.-L.; Hsu Y.-C.; Hsu C.-W.; Wu C.-Y.; Wu J.-C.; Cheng J.C.-H.; Leung S.W.; Chen S.-W.; Hsu H.-C.; Hong J.-H.; Wang P.-M.; Wang P.-M.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; CHIUN HSU; Chao Y.; Chen L.-T.; Lee P.-H.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Hung C.-F.; Huang S.-F.; Yang S.-S.; Chen R.-C.; Chen C.-H.; Dai C.-Y.; Wang T.-E.; Su C.-W.; Wang J.-H.; Lu S.-N. |
| 臺大學術典藏 |
2022-08-19T00:20:38Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; CHIUN HSU; Lin Z.-Z.; Liu T.-H.; Shao Y.-Y.; Lu L.-C. |
| 臺大學術典藏 |
2022-08-19T00:20:38Z |
Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma
|
Hsu P.-N.; Cheng A.-L.; CHIUN HSU; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu C.-L.; Lin Y.-Y.; Ou D.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:37Z |
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M.; Ikeda M.; Chopra A.; Numata K.; Yeo W.; Kang Y.-K.; Hou M.-M.; Kim T.-Y.; Choo S.-P.; CHIUN HSU; Yau T. |
| 臺大學術典藏 |
2022-08-19T00:20:36Z |
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients
|
Yeh K.-H.; Cheng A.-L.; Tien Y.-W.; Kuo S.-H.; CHIUN HSU; Yang S.-H.; Guo J.-C. |
| 臺大學術典藏 |
2022-08-19T00:20:36Z |
Corrigendum to ��Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis�� [J Hepatol 71 (2019) 543�V552](S0168827819303009)(10.1016/j.jhep.2019.05.014)
|
Kudo M.; Dela Cruz C.; Anderson J.; Zhao H.; Chao Y.; Moriguchi M.; Kuromatsu R.; Ikeda M.; Yeo W.; Chopra A.; Yau T.; CHIUN HSU; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K. |
| 臺大學術典藏 |
2022-08-19T00:20:36Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Liu T.-H.; CHIUN HSU; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:36Z |
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
|
Cheng A.-L.; CHIUN HSU; Taiwan Cooperative Oncology Group; Chen P.-J.; Tsui C.-W.; Wu H.-Y.; Hsu Y.-T.; Chuang M.-H.; Hsiung C.A.; Liu T.-W.; Yang H.-C.; Hsiao C.-F.; Tsou H.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:35Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
Cheng A.-L.; CHIUN HSU; Chan S.L.; Choo S.-P.; Kudo M. |
| 臺大學術典藏 |
2022-08-19T00:20:34Z |
An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas
|
Chen M.-H.; Chou W.-C.; Hsiao C.-F.; Jiang S.S.; Tsai H.-J.; Liu Y.-C.; CHIUN HSU; Shan Y.-S.; Hung Y.-P.; Hsich C.-H.; Chiu C.-H.; Liu T.-C.; Cho S.-F.; Liu T.-W.; Chao Y. |
| 臺大學術典藏 |
2022-08-19T00:20:34Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Douillard J.-Y.; Yoshino T.; Yen Y.; Hsu C.-H.; Tabernero J.; Shen Y.-C.; CHIUN HSU; Chen S.-C.; Huang Y.-H.; Yen C.-J.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Pentheroudakis G.; Cheng A.-L.; Chen L.-T.; Martinelli E. |
